Medpage Today on MSN3d
Primary Biliary Cholangitis Incidence and Prevalence Growing
Primary biliary cholangitis (PBC) has typically been considered a rare condition, with a pooled global estimated incidence of ...
Medpage Today on MSN4d
Managing Primary Biliary Cholangitis Progression and Symptoms
Once clinical suspicion has been established for primary biliary cholangitis (PBC), the "serologic hallmark" of the ...
Gilead’s Livdelzi (Seladelpar) Demonstrated a Sustained Efficacy and Long-Term Safety Profile in Management of Primary Biliary Cholangitis
Gilead Sciences, Inc. (Nasdaq: GILD) today announced data from a two-and-a-half-year interim analysis from the ongoing Phase ...
PharmiWeb19h
Iqirvo® (elafibranor) data show efficacy and tolerability for up to 3 years in patients with PBC with improvements in fatigue and pruritus
Ipsen presents three late-breaking presentations and eight abstracts across rare cholestatic liver disease portfolio at AASLD 2024Elafibranor was granted marketing authorisation for the treatment of ...
GSK drug meets main goal in late-stage study to treat relentless itch
British drugmaker GSK said on Tuesday its experimental therapy, linerixibat, met its main goal in a late-stage trial to treat ...
Monthly Prescribing Reference5d
FDA Denies Full Approval of Obeticholic Acid for Primary Biliary Cholangitis
The sNDA was submitted to support full approval of OCA for this indication based on data from the COBALT trial, as well as real-world evidence.
Morningstar4d
Gilead’s Livdelzi (Seladelpar) Demonstrated a Sustained Efficacy and Long-Term Safety Profile in Management of Primary Biliary Cholangitis
ASSURE is an open label study to evaluate the long-term safety and tolerability of seladelpar in people with primary biliary cholangitis (PBC) who have already participated in other PBC clinical ...
National Institute for Health and Care Excellence5d
Elafibranor for previously treated primary biliary cholangitis
Elafibranor (Iqirvo) is available on the NHS. It is a possible treatment for primary biliary cholangitis in adults, when used: with ursodeoxycholic acid (UDCA), if the condition has not responded well ...
National Institute for Health and Care Excellence5d
Elafibranor for previously treated primary biliary cholangitis
There is a simple discount patient access scheme for elafibranor. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...